MILFORD, Mass., April 8, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2025 financial results conference call on Tuesday, May 6th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 3rd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separ ...

News Summary "The addition of the Alliance iS Bio HPLC System with PDA detection allows biopharmaceutical laboratories to perform enhanced spectral analysis, including impurity detection, peak purity analysis, multi-wavelength detection, and method validation, to deliver safe and effective products," said Fraser McLeod, Vice President, General Manager, QA/QC, at Waters Corporation. "Built on the Alliance iS HPLC Platform, the system is designed to simplify the analysis of complex biopharmaceuticals in devel ...

BP plc (BP) , the UK-based energy major, and Azerbaijan’s SOCAR have entered Israel’s offshore gas sector through a joint licensing agreement with NewMed Energy, the Israeli Energy Ministry announced on Monday. The deal grants exploration rights in Zone I of Israel’s Exclusive Economic Zone, marking BP’s first venture in Israel and SOCAR’s first exploration project outside Azerbaijan.The three-party consortium, consisting of BP, SOCAR and NewMed Energy, secured the rights to Zone I after winning a competiti ...

Company Overview - Winnebago Industries, Inc. (NYSE: WGO) is a prominent player in the RV and recreational boat sectors, established in 1958 and recognized for its RVs [1] - The company expanded its portfolio by acquiring luxury boat manufacturer Chris-Craft in 2018 and also purchased Barletta [1] Analyst Background - Ian Bezek, a former hedge fund analyst at Kerrisdale Capital, has extensive experience in Latin American markets, focusing on countries like Mexico, Colombia, and Chile [2] - He specializes in identifying high-quality compounders and growth stocks at reasonable prices in the US and other developed markets [2]

MILFORD, Mass., March 7, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11th, 2025 at 10:00AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Wat ...

Company Overview - Waters Corporation operates in over 35 countries with approximately 7,600 employees and offers products in more than 100 countries[12]. - The company has two operating segments: Waters, focusing on LC and MS systems, and TA, specializing in thermal analysis instruments[15]. - Waters believes it is one of the largest manufacturers of LC and LC-MS systems, chromatography columns, and related services globally[36]. - The company employed approximately 7,600, 7,900, and 8,200 employees at December 31 for 2024, 2023, and 2022, respectively, with about 39% located in the United States[72]. - The company has approximately 1,100, 1,200, and 1,200 employees involved in research and development efforts at the end of 2024, 2023, and 2022, respectively[68]. Product Development and Innovation - In 2023, Waters introduced the DynaPro ZetaStar instrument for nanoparticle analysis, enhancing sensitivity and measurement speed[21]. - The Alliance iS HPLC System was launched to reduce compliance risk and improve measurement accuracy, integrating with cloud-native monitoring software[28]. - Waters introduced the new Oasis WAX/GCB and GCB/WAX cartridges for PFAS analysis, ensuring low residual PFAS through accredited QC testing[29]. - The company launched the Xevo TQ Absolute System, the most sensitive benchtop tandem mass spectrometer in its class, in 2022[35]. - The company has expanded its product line with the introduction of HPLC CONNECT software for enhanced digital synchronization between systems[22]. - In 2024, Waters introduced the Alliance iS Bio HPLC System, designed to eliminate up to 40% of common errors in biopharma quality control[29]. - The introduction of the Battery Cycler Microcalorimeter Solution in 2023 significantly reduces experiment time from months to weeks for battery cell characterization[50]. - The new SELECT SERIES MRT System now offers 50% higher resolution, achieving 300,000 FWHM resolution, and a 3X faster scan rate[40]. Financial Performance - The Company’s total net sales for 2024 were $2,958,387 thousand, flat compared to 2023 and down 1% from 2022[186]. - Product sales decreased by 3% in 2024 to $1,844,176 thousand, while service sales increased by 6% to $1,114,211 thousand[186]. - Operating income for 2024 was $826,353 thousand, a 1% increase from $817,676 thousand in 2023[190]. - Net income for 2024 was $637,834 thousand, a slight decrease of 1% from $642,234 thousand in 2023[192]. - The effective tax rate for 2024 was 15.5%, compared to 12.8% in 2023[192]. - The Company generated $762 million in net cash flow from operating activities in 2024, an increase from $603 million in 2023[193]. - Capital expenditures for 2024 were $142 million, down from $161 million in 2023, primarily due to the completion of new manufacturing facilities[194]. Market and Sales Dynamics - The Company’s pharmaceutical segment accounted for 58% of net sales in 2024, with 31% from other industrial accounts and 11% from academic institutions and governmental agencies[52]. - In 2024, the Company generated $397 million in total net sales from China, a significant 30% decrease from $565 million in 2022 due to lower customer demand and economic conditions[92]. - Approximately 68% of the Company's net sales in 2024 were outside the United States, primarily denominated in foreign currencies, exposing the Company to foreign currency exchange rate fluctuations[1]. - Sales in China declined by 10% in 2024 and 22% in 2023, primarily due to lower demand and increased government regulations[187]. - Approximately 58% of the Company's net sales in 2024 were to worldwide pharmaceutical accounts, which are subject to unfavorable market conditions[102]. Acquisitions and Investments - Waters has made significant acquisitions, including Wyatt Technology in May 2023, to enhance its product offerings[14]. - The Company completed the acquisition of Wyatt Technology, LLC for a total purchase price of $1.3 billion in cash, expanding its portfolio and exposure to large molecule applications[185]. - The financial results for the year ended December 31, 2024, include the full-year results of Wyatt, while the results for 2023 included only seven-and-a-half months of Wyatt's financial results[185]. - The Company financed the Wyatt acquisition in May 2023 through borrowings, resulting in a significant increase in outstanding debt[109]. Operational Challenges and Risks - The Company anticipates potential risks from foreign currency exchange rate fluctuations and geopolitical instability affecting its operations[87]. - The Company is subject to risks from global economic conditions, including inflation and interest rate changes, which may affect demand for its products[97]. - The Company faces competition from major players such as Agilent Technologies, Shimadzu Corporation, and Thermo Fisher Scientific, among others, in the analytical instrument systems market[78]. - The Company is subject to risks from global economic conditions, including inflation and interest rate changes, which may affect demand for its products[97]. - The Company is subject to various legal and regulatory proceedings that can divert management attention and incur significant expenses[151]. Workforce and Development - The Company has made significant investments in workforce development and inclusion initiatives to enhance talent retention and development[71]. - The Company reduced its worldwide workforce by approximately 5% during 2024 and 2023 to align resources with growth strategies, which may impact productivity and customer relationships[129]. - The Company experienced a reduction in workforce impacting about 2% of its employees, primarily in China, due to the decline in sales[92]. Environmental, Social, and Governance (ESG) - The company published its 2024 ESG Report in November 2024, detailing efforts to address environmental impact and uphold social responsibilities[83]. - The Company is committed to monitoring environmental regulations, particularly in the European Union and China, regarding hazardous substances in electronic equipment[66]. - The Company may incur significant costs related to compliance with evolving environmental, social, and corporate governance (ESG) expectations[150]. - The Company is evaluating its supply chain for conflict minerals and plans to file its 2024 Form SD with the SEC in May 2025[145]. Cybersecurity and Compliance - Cybersecurity threats pose risks to the Company's technology infrastructure, which could lead to interruptions and material adverse effects on business operations[134]. - The Company has implemented a robust cybersecurity risk management framework, including annual audits and vulnerability assessments[161]. - The Company has invested resources to protect its technology infrastructure, but risks remain regarding potential security incidents[135]. - The Company faces risks related to compliance with complex regulations, which could result in fines, product recalls, or operational restrictions[139]. Shareholder Returns and Stock Performance - The Company has not declared or paid any dividends on its common stock in the past three fiscal years and does not intend to pay cash dividends in the foreseeable future[176]. - The Company has a remaining authorization of $1.0 billion for share repurchases, with the program extended through January 21, 2028[183]. - The Company’s stock price performance from December 31, 2019, to December 31, 2024, shows a cumulative total return of 58.78%[182].

Waters Corporation (NYSE: WAT ) reported their Q4’24 and FY’24 results on February 12 and the results came in better than expected. Over the last few quarters, the company has been coming out of a downturn in instruments thatI'm an insurance Case Manager with a deep interest in investing. My investment philosophy is all about buying high quality stocks and great businesses. My favorite businesses are those led by disciplined capital allocators, earn exceptional returns on capital, and can compound their inv ...

Core Insights - Waters Corporation reported strong fourth-quarter 2024 results with non-GAAP earnings of $4.10 per share, exceeding the Zacks Consensus Estimate by 1.99% and reflecting a 13.3% year-over-year increase from $3.62 [1][3] - Net sales reached $872.7 million, surpassing the Zacks Consensus Estimate of $857 million, marking a 6.5% increase on a reported basis and an 8% increase on a constant-currency basis compared to the previous year [2][3] Financial Performance - The company experienced double-digit growth in the Pharma segment, with instrument sales and recurring revenue showing high-single-digit gains in constant currency [3] - Non-GAAP selling and administrative expenses decreased by 2.6% year-over-year to $168.5 million, representing a contraction of 180 basis points as a percentage of net sales [8] - Research and development spending rose by 8.9% year-over-year to $46.3 million, with the adjusted operating margin increasing by 60 basis points to 35.5% [9] Sales Breakdown - Waters operates under two segments: Waters (87.6% of net sales) with sales of $764.3 million, up 6.6% year-over-year, and TA (12.4% of net sales) with sales of $108.4 million, reflecting 5.7% growth [4] - Sales by product category included Instruments at $419.6 million (48.1% of net sales, up 5.6%), Services at $301.8 million (34.6% of net sales, up 8.2%), and Chemistry at $151.3 million (17.3% of net sales, up 5.5%) [5] Market and Geographic Performance - The Pharmaceutical market generated $498.8 million in sales (57.2% of net sales), increasing by 7.6% year-over-year, while the Industrial market saw sales of $264 million (30.3% of net sales, up 1.5%) and the Governmental and Academic market generated $109.9 million (12.6% of net sales, up 15%) [6] - Geographic sales included Asia at $272.9 million (31.3% of net sales, up 4.2%), the Americas at $321 million (36.8% of net sales, up 5.7%), and Europe at $278.8 million (31.9% of net sales, up 9.8%) [7] Cash Flow and Guidance - As of December 31, 2024, Waters had cash, cash equivalents, and investments totaling $325.4 million, with cash from operations increasing to $240.1 million from $204.6 million in the prior quarter [10] - For Q1 2025, Waters expects non-GAAP earnings of $2.17-$2.25 per share, with organic sales growth anticipated at 4-7% on a constant-currency basis, while total sales growth is projected at 1-4% [11][12]

Financial Data and Key Metrics Changes - In Q4 2024, sales grew 6.4% as reported and 8% in constant currency, exceeding the high end of guidance [13][38] - Non-GAAP EPS was $4.10, reflecting 13% growth, while GAAP EPS was $3.88 [15][48] - For the full year, non-GAAP EPS grew 1% to $11.86, including a 5% decline due to foreign exchange headwinds [16][48] Business Line Data and Key Metrics Changes - Pharma sales grew 10% in Q4, driven by low double-digit growth in Europe and Asia, and high single-digit growth in the Americas [17] - Recurring revenues grew 6% for the full year, with chemistry consumables and service businesses showing resilience [43] - Instruments grew 8% in Q4, with significant contributions from liquid chromatography and mass spectrometry [42] Market Data and Key Metrics Changes - By geography, Europe grew 11%, Asia 9%, and Americas 6% in Q4 [19] - In China, sales returned to positive growth, up low single digits [19] - The PFAS testing market is valued at $400 million, growing at 20% annually, with Waters growing over 40% in this segment [23] Company Strategy and Development Direction - The company is focused on high-volume life science applications, capitalizing on new product launches and customer needs [11][27] - There is an expectation of continued growth in the analytical instruments market, driven by instrument replacement cycles and new applications [30][33] - The company plans to maintain margin expansion and operational excellence while exploring M&A opportunities [51][55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of customer CapEx spending and instrument replacement, expecting strong momentum into 2025 [12][35] - The guidance for 2025 anticipates constant currency sales growth of 4.5% to 7%, with a focus on operational performance to counteract foreign exchange headwinds [36][54] - Management highlighted the importance of new product performance and customer engagement in driving future growth [76][94] Other Important Information - Free cash flow for Q4 was $188 million, with a full-year total of $744 million, representing 25% of sales [49] - The company reduced debt by approximately $200 million in Q4, with a net debt position of about $1.3 billion [50] - The company is evaluating the resumption of its share repurchase program in 2025 [51] Q&A Session Summary Question: Can you discuss budget flush dynamics and the replacement cycle? - Management noted a typical budget flush in Q4, with high single-digit instrument growth and strong performance in large pharma driving the replacement cycle [66][68] Question: How are macro-related risks incorporated into guidance? - Management indicated that the guidance reflects strong performance in Pharma and recurring revenues, with prudence built into the lower end of the guidance [74][78] Question: What is the contribution of GLP-1 and PFAS testing to growth? - Management expects both GLP-1 and PFAS testing to contribute 30 basis points each to growth, with India expected to add 70 to 100 basis points [84] Question: How does the company view the academic market in light of NIH cuts? - Management acknowledged uncertainties in the academic market but maintained a cautious optimism based on strong performance in other segments [90][92] Question: What are the dynamics in Europe and India? - Management highlighted strong growth in both regions, with India benefiting from a significant generics opportunity and Europe seeing broad-based growth across segments [98][102]

Q4 2024 Earnings Call Presentation February 12, 2025 Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements regarding future results and events, including financial and operational guidance and projected estimates. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "outlook," and similar expressions (as w ...